ERBB2 and breast cancer: Tuffaha et al. reported the cost-effectiveness of the gBRCA testing established at the 10% pretest probability threshold [43]; hence expanding the gBRCA test from TNBC to all HER2-negative BC patients is potentially cost-effective, considering the high prevalence (~9.7%) of gBRCA mutations in HER2-negative BC patients.